Company profile
ENANTA PHARMACEUTICALS INC
NASDAQ:ENTABiotechnology: Pharmaceutical Preparations
Drug pipeline (5)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| EDP-305 | phase2 | — | 9 | completed, terminated |
| MODITHROMYCIN | phase2 | — | 1 | unknown |
| Zelicapavir | phase2 | — | 10 | completed, terminated |
| Zevotrelvir | phase2 | — | 4 | no active trials |
| ALISPORIVIR | phase1 | — | 1 | no active trials |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (45)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04971512 | phase1 | terminated | 2021-08-02 | 2021-12-20 | Enanta Pharmaceuticals, Inc | A 2 PART STUDY EVALUATING EDP-721 IN HEALTHY SUBJECTS AND EDP-721 IN COMBINATION WITH EDP-514 IN PATIENTS WITH CHRONIC HEPATITIS B VIRUS INFECTION. |
| NCT06170242 | phase2 | completed | 2023-11-20 | 2024-06-17 | Enanta Pharmaceuticals, Inc | A Controlled Phase 2a Study to Evaluate the Efficacy of EDP-323 Against Respiratory Syncytial Virus Infection in a Virus Challenge Model |
| NCT06847464 | phase1 | completed | 2025-01-27 | 2025-05-24 | Enanta Pharmaceuticals, Inc | A Drug-Drug Interaction Study to Evaluate the Effects of Itraconazole, Carbamazepine, Quinidine and Fluconazole on the Pharmacokinetics and Safety of EDP-323. |
| NCT03783897 | phase1 | completed | 2018-11-27 | 2019-06-04 | Enanta Pharmaceuticals, Inc | A Drug-drug Interaction Study to Investigate the Effect of Coadministration of EDP-305 on the PK of a Combined Oral Contraceptive in Healthy Female Subjects |
| NCT07482657 | phase2 | recruiting | 2026-07-09 | 2026-12-01 | Enanta Pharmaceuticals, Inc | A Phase 2 Study to Investigate the Efficacy and Safety of Zelicapavir in Participants Aged ≥28 Days to ≤36 Months of Age Infected With Respiratory Syncytial Virus |
FDA applications (0)
No records yet.